This site is intended for healthcare professionals

Merck Inc., + Ridgeback Biotherapeutics provide update on progress of clinical development program for molnupiravir, an investigational oral antiviral for the treatment of mild-to-moderate COVID-19.

Read time: 3 mins
Last updated:16th Apr 2021
Published:16th Apr 2021
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest